Van Lanschot NV/ NL0000302636 /
- - | Chg. - | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
-USD | - | 2 Turnover: - |
-Bid Size: - | -Ask Size: - | 1.73 bill.USD | - | - |
GlobeNewswire
03-04
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
GlobeNewswire
02-29
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and...
GlobeNewswire
2023-12-22
Zealand Pharma enters into EUR 90 million finance agreement with the European Investment Bank
GlobeNewswire
2023-10-10
Renovaro Biosciences Appoints Two Finance Industry Experts to Board of Directors
euro adhoc
2021-09-09
EANS-News: Atrium European Real Estate Limited / Publication of Scrip Dividend Circular Q3 2021 CNE
euro adhoc
2021-06-09
EANS-News: Atrium European Real Estate Limited / Publication of Scrip Dividend Circular Q2 2021 CNE
GlobeNewswire
2021-02-09
SEQUANA MEDICAL SUCCESSFULLY RAISES EUR 22.5 MILLION IN AN EQUITY PLACEMENT
GlobeNewswire
2020-06-26
Hyloris Pharmaceuticals Raises approximately EUR 61.81 million in Successful Initial Public Offering
GlobeNewswire
2020-06-24
Hyloris Pharmaceuticals Announces Narrowing of Price Range of its Initial Public Offering
GlobeNewswire
2020-06-19
Hyloris Pharmaceuticals Announces Coverage of the Maximum Offering Size, including Increase Option a...
GlobeNewswire
2020-06-18
Hyloris Pharmaceuticals Announces the Coverage of the Base Offering Throughout the Price Range of it...
GlobeNewswire
2020-06-17
Hyloris Pharmaceuticals launches its Initial Public Offering on Euronext Brussels